Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.
|ClinicalTrials.gov Identifier: NCT01860586|
Recruitment Status : Completed
First Posted : May 22, 2013
Results First Posted : April 17, 2017
Last Update Posted : April 17, 2017
|Condition or disease||Intervention/treatment|
|Retinal Detachment Vitreoretinopathy Proliferative||Drug: Bevacizumab|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Outcomes were compared to a retrospective, historical control group.|
|Masking:||None (Open Label)|
|Official Title:||A Prospective Pilot Study Evaluating the Effect of Intravitreal Injection of Bevacizumab on Recurrent Retinal Detachment Due to Proliferative Vitreoretinopathy|
|Study Start Date :||June 2013|
|Primary Completion Date :||November 2014|
|Study Completion Date :||November 2014|
Bevacizumab will be injected into the study eye at end of retinal detachment (rd) surgery and monthly for the following 3 months (total of 4 intravitreal bevacizumab injections)
Bevacizumab (1.25mg/0.05mL) will be injected into the study eye, at the end of the surgical repair of the retinal detachment and at Month 1, 2 and 3.
- The Effect of Intravitreal Bevacizumab Injections on Rate of Recurrent Retinal Detachment (Increase or Decrease) [ Time Frame: up to 6 months ]This will be assessed by the frequency (occurences) of retinal detachments in patients that have intravitreal bevacizumab injections versus prior patients that did not have intravitreal bevacizumab injections.
- The Effect of Intravitreal Bevacizumab Injections on the Development of Epiretinal Membranes (Increase or Decrease) [ Time Frame: 6 months ]To determine if intravitreal bevacizumab injections will increase or decrease the occurences (cases) of epiretinal membranes .
- Intravitreal Bevacizumab Injections Impact on Visual Acuity Score (Change in Letters Read). [ Time Frame: 6 months ]Increase or decrease in amount of letters read after intravitreal bevacizumab injections versus control patient that did not receive injections of intravitreal bevacizumab.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01860586
|United States, Pennsylvania|
|Mid Atlantic Retina- Wills Eye Institute|
|Philadelphia, Pennsylvania, United States, 19107|
|Principal Investigator:||Jason Hsu, MD||WillsEye Hospital|